Figure 8

SPM production is increased in human plasma via ω-3 PUFA supplementation and immunologic challenge. (A) Total SPM cluster concentrations in human plasma with ω-3 PUFA supplementation or placebo 1–168 h post intravenous LPS injection; *P < 0.05, **P < 0.01 for ω-3 PUFA supplement group vs. placebo group with one-tailed ratio t-test. (B) Comparison of total SPM cluster concentrations in human plasma at 2 h between separate laboratories. Results are means ± SEM of 3 healthy subjects; *P < 0.05; ns = not statistically different using paired one-tailed ratio t-test.